Childhood Cancer Genomics (PDQ®)–Health Professional Version

SECTIONS

Changes to this Summary (10/05/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Leukemias

Added text to the Acute Lymphoblastic Leukemia (ALL) subsection to state that approximately two-thirds of patients with ALL and germline pathogenic TP53 variants have hypodiploid ALL (cited Qian et al. as reference 35).

Added text to the Acute Lymphoblastic Leukemia (ALL) subsection about the outcomes of patients with BCR-ABL1–like ALL (cited Roberts et al. as reference 96).

Added text to the Acute Lymphoblastic Leukemia (ALL) subsection to state that the prevalence of targetable kinase fusions in BCR-ABL1–like ALL is lower in National Cancer Institute (NCI) standard-risk patients than in NCI high-risk patients.

Added text to the Acute Lymphoblastic Leukemia (ALL) subsection to state that there are few published results of changing therapy on the basis of IKZF1 gene status. Also added text about the results of two Malaysia-Singapore group trials, where in the first trial, IKZF1 status was not considered in risk stratification, while in the subsequent trial, IKZF1-deleted patients were excluded from the standard-risk group (cited Yeoh et al. as reference 116 and level of evidence 2A).

Kidney Tumors

Revised text in the Wilms Tumor subsection to state that children with WAGR syndrome (Wilms tumor, aniridia, genitourinary anomalies, and mental retardation) are at high risk (approximately 50%) of developing Wilms tumor (cited Scott et al. as a reference 24).

Added text to the Wilms Tumor subsection to state that for patients with Beckwith-Wiedemann syndrome, the risk of developing Wilms tumor is 4.1%. Also added text to state that for patients with Beckwith-Wiedemann syndrome, the relative risk of developing hepatoblastoma is 2,280 times that of the general population.

Added text to the Wilms Tumor subsection about the results of a study of 118 patients with diffuse anaplastic Wilms tumor registered on the National Wilms Tumor Study-5 trial that explored the significance of TP53 mutations (cited Ooms et al. as reference 68).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Multiple Endocrine Neoplasia Syndromes

Next section >
About This PDQ Summary